eFFECTOR Therapeutics, Inc. (EFTR)
| Market Cap | 3.76K +300.0% |
| Revenue (ttm) | n/a |
| Net Income | -34.63M |
| EPS | -12.42 |
| Shares Out | 4.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331 |
| Open | 0.0002 |
| Previous Close | 0.0008 |
| Day's Range | 0.0002 - 0.0008 |
| 52-Week Range | 0.0002 - 0.0200 |
| Beta | 2.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company’s lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinica... [Read more]
Financial Performance
Financial StatementsNews
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that de...
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind ...
eFfector Therapeutics to collaborate with Dana-Farber Cancer Institute
eFFECTOR Therapeutics announced a collaboration to conduct an investigator-sponsored trial evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positiv...
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (S...
eFfector Therapeutics reports Q1 EPS ($2.16), consensus ($2.16)
The company had cash, cash equivalents, and short-term investments totaling $25.4M as of March 31 compared to $18.4M as of December 31. The company anticipates that its current cash, cash…
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024 Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into...
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...
eFFECTOR Therapeutics trading resumes
09:00 EDT eFFECTOR Therapeutics trading resumes
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors ...
eFFECTOR Therapeutics trading halted, news pending
08:25 EDT eFFECTOR Therapeutics trading halted, news pending
eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
Revenue was zero for the quarter ended December 31 compared to approximately $0.7M for the same quarter of 2022. Revenue for the full year of 2023 was zero, compared to…
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in early April 2024
eFfector Therapeutics target adjusted to $24 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on eFfector Therapeutics to $24 from $5 and keeps a Buy rating on the shares. The target adjustment reflects the 1-for-25 reverse stock…
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (...
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regula...
eFFECTOR Therapeutics Secures $15M in Direct Offering
eFFECTOR Therapeutics (EFTR) has released an update to notify the public and investors about an entry into a material definitive agreement. eFFECTOR Therapeutics, Inc. has entered into a Securities Pu...
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regula...
eFfector Therapeutics to hold a virtual investor meeting
Virtual Investor Research & Development Day to be held on January 24 at 4:30 pm. Webcast Link
eFfector Therapeutics to hold a virtual investor meeting
Virtual Investor Research & Development Day to be held on January 24 at 4:30 pm. Webcast Link
eFfector Therapeutics to hold a virtual investor meeting
Virtual Investor Research & Development Day to be held on January 24 at 4:30 pm. Webcast Link
eFFECTOR Therapeutics trading halted, news pending
19:50 EST eFFECTOR Therapeutics trading halted, news pending
eFfector Therapeutics board approves 1-for-25 reverse stock split
eFFECTOR Therapeutics announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The reverse stock split will become effective at 12:01 A.M.
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansion ...
eFFECTOR Therapeutics Announces Reverse Stock Split
EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients